Basal Plus GLP1-ra on Glycemic Variability in CKD

NCT05218915 on ClinicalTrials.gov · last registry update 2024-12-03

Finished 30 October 2024, after enrolling 95 people. Primary outcome, as filed: Glycemic variability. dulaglutide is approved in the US, but not for diabetes and diabetic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: Elaine Chow
Sponsor type: Other
Enrollment: 95
Started: 2022-01-28
Primary completion: 2024-10-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glycemic variability

Conditions studied

Diabetes Mellitus · Diabetic Kidney Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.